Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024
November 07, 2023 at 01:00 am EST
Share
Santen Pharmaceutical Co., Ltd. revised consolidated earnings forecasts for the fiscal year ending March 31, 2024. For the year, on a core basis, the company expects revenue of ¥302,000 million, core operating profit of ¥58,000 million, core net profit for the year of ¥43,500 million and basic core earnings per share of ¥118.87 compared to the previous guidance of revenue of ¥285,000 million, core operating profit of ¥50,000 million, core net profit for the year of ¥37,500 million and basic core earnings per share of ¥102.47 provided earlier.
On IFRS basis, the company expects revenue of ¥302,000 million, operating profit of ¥41,000 million, net profit for the year of ¥29,500 million and basic earnings per share of ¥80.64 compared to the previous guidance of guidance of revenue of ¥285,000 million, core operating profit of ¥35,000 million, core net profit for the year of ¥25,000 million and basic core earnings per share of ¥68.34 provided earlier.
SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.